2.96
0.24 (8.82%)
| Previous Close | 2.72 |
| Open | 2.68 |
| Volume | 961,200 |
| Avg. Volume (3M) | 304,011 |
| Market Cap | 1,827,802,368 |
| Price / Book | 20.15 |
| 52 Weeks Range | |
| Earnings Date | 31 Mar 2025 |
| Diluted EPS (TTM) | -0.390 |
| Total Debt/Equity (MRQ) | 522.50% |
| Current Ratio (MRQ) | 0.200 |
| Operating Cash Flow (TTM) | -125.74 M |
| Levered Free Cash Flow (TTM) | -134.61 M |
| Return on Assets (TTM) | -17.81% |
| Return on Equity (TTM) | -242.61% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | IMMUNOTECH-B | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.63 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| IMMUNOTECH-B | 2 B | - | - | 20.15 |
| CSTONE PHARMA-B | 14 B | - | - | 27.87 |
| CKLIFE SCIENCES | 7 B | - | - | 1.88 |
| VIVA BIOTECH | 4 B | - | 28.57 | 0.940 |
| ANTENGENE-B | 3 B | - | - | 2.84 |
| SINOMAB BIO-B | 2 B | - | - | 4.23 |
|
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 72.90% |
| % Held by Institutions | 6.41% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |